| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.32 | 0.05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.05 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.06 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.1 | 0.06 |